Jesus C. Fabregas

Gray zone lymphoma with features intermediate between classical<scp>H</scp>odgkin lymphoma and diffuse large<scp>B</scp>‐cell lymphoma:<scp>C</scp>haracteristics, outcomes, and prognostication among a large multicenter cohort

Andrew M. Evens, Jennifer A. Kanakry, Laurie H. Sehn et al. · American Journal of Hematology · 2015 · 83 citations · Full text

Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors

Claudia Marcela Diaz, Alberto Chiappori, Luigi Aurisicchio et al. · Journal of Translational Medicine · 2013 · 77 citations · Full text

Phase II study of⁹⁰Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma

Izidore S. Lossos, Jesus C. Fabregas, Tulay Koru‐Sengul et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2014 · 27 citations

Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.

Thomas J. George, Greg Yothers, Samuel A. Jacobs et al. · Journal of Clinical Oncology · 2022 · 25 citations

Surgical Oncology, Pathology, Phase Ii Study +17

Association of social determinants of health with late diagnosis and survival of patients with pancreatic cancer

Jesus C. Fabregas, Kristen E. Riley, Jeannine M. Brant et al. · Journal of Gastrointestinal Oncology · 2022 · 23 citations · Full text